Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Admir Malaj"'
Publikováno v:
Antibiotics, Vol 12, Iss 5, p 882 (2023)
There are growing concerns with rising antimicrobial resistance (AMR) across countries. These concerns are enhanced by the increasing and inappropriate utilization of ‘Watch’ antibiotics with their greater resistance potential, AMR is further exa
Externí odkaz:
https://doaj.org/article/76d902643ec44da0bb451a776580cc65
Autor:
Evelien Moorkens, Brian Godman, Isabelle Huys, Iris Hoxha, Admir Malaj, Simon Keuerleber, Silvia Stockinger, Sarah Mörtenhuber, Maria Dimitrova, Konstantin Tachkov, Luka Vončina, Vera Vlahović Palčevski, Gnosia Achniotou, Juraj Slabý, Leona Popelková, Kateřina Kohoutová, Dorthe Bartels, Ott Laius, Jaana E. Martikainen, Gisbert W. Selke, Vasileios Kourafalos, Einar Magnússon, Rannveig Einarsdóttir, Roisín Adams, Roberta Joppi, Eleonora Allocati, Arianit Jakupi, Anita Viksna, Ieva Greičiūtė-Kuprijanov, Patricia Vella Bonanno, Vincent Suttorp, Øyvind Melien, Robert Plisko, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Corinne Zara, Vanda Marković-Peković, Nataša Grubiša, Gustaf Befrits, Robert Puckett, Arnold G. Vulto
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2021)
Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry.Objectives: The aim of thi
Externí odkaz:
https://doaj.org/article/91efa0738a404ac58954a5cf23bc3c10
Autor:
Tomasz Bochenek, Vafa Abilova, Ali Alkan, Bogdan Asanin, Iñigo de Miguel Beriain, Zeljka Besovic, Patricia Vella Bonanno, Anna Bucsics, Michal Davidescu, Elfi De Weerdt, Natasa Duborija-Kovacevic, Jurij Fürst, Mina Gaga, Elma Gailīte, Jolanta Gulbinovič, Emre U. Gürpınar, Balázs Hankó, Vincent Hargaden, Tor A. Hotvedt, Iris Hoxha, Isabelle Huys, Andras Inotai, Arianit Jakupi, Helena Jenzer, Roberta Joppi, Ott Laius, Marie-Camille Lenormand, Despina Makridaki, Admir Malaj, Kertu Margus, Vanda Marković-Peković, Nenad Miljković, João L. de Miranda, Stanislav Primožič, Dragana Rajinac, David G. Schwartz, Robin Šebesta, Steven Simoens, Juraj Slaby, Ljiljana Sović-Brkičić, Tomas Tesar, Leonidas Tzimis, Ewa Warmińska, Brian Godman
Publikováno v:
Frontiers in Pharmacology, Vol 8 (2018)
Drug shortages have been identified as a public health problem in an increasing number of countries. This can negatively impact on the quality and efficiency of patient care, as well as contribute to increases in the cost of treatment and the workloa
Externí odkaz:
https://doaj.org/article/f304e555cf57479f958214a3ac31c61a
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 10, Iss 1 (2017)
Background The inappropriate use of antimicrobials is a problem worldwide. To target future interventions, a thorough understanding of the reasons behind this current behaviour is needed. Within the EU, the culture of antimicrobial use has been inten
Externí odkaz:
https://doaj.org/article/2dbf043901d54eb794e79aca6e0f0935
Autor:
Wouter Hamelinck, Elita Poplavska, Ott Laius, Ruaraidh Hill, Jurij Fürst, Dzintars Gotham, Iva Selke Krulichová, Zornitza Mitkova, Ileana Mardare, Andrew F. Hill, Stuart McTaggart, Brian Godman, Corrine Zara, Vanda Marković-Peković, Patricia Vella Bonanno, Mark Parker, Caridad Pontes, Katarina Banasova, Tanja Novakovic, John Yfantopoulos, Janet Wale, Irene Langner, Hans Piepenbrink, Christian Hierländer, Peter Skiold, Guenka Petrova, Magdalene Wladysiuk, Amanj Kurdi, Vincent de Valk, Stephen Campbell, Anna Nachtnebel, Admir Malaj, Roberta Joppi, Angela Timoney, Maria Juhasz-Haverinen, Antony P. Martin, Jolanta Gulbinovič, Merce Obach Cortadellas, Iris Hoxha, Arianit Jakupi, Durhane Wong-Rieger, Catherine Sermet, D Tomek, Gisbert Selke, Eleonora Allocati, Ieva Greiciute-Kuprijanov, Tomasz Bochenek, Steven Simoens, Robert Plisko
Publikováno v:
University of Strathclyde
Introduction/Objectives: Health authorities are facing increasing challenges to the sustainability of their healthcare systems because of the growing expenditures on medicines, including new, high-priced oncology medicines, and changes in disease pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d77151d4ac5e7399df29d92a7faac2a6
https://strathprints.strath.ac.uk/75033/1/Godman_etal_GABI_2021_Variation_in_the_prices_of_oncology_medicines_across_Europe.pdf
https://strathprints.strath.ac.uk/75033/1/Godman_etal_GABI_2021_Variation_in_the_prices_of_oncology_medicines_across_Europe.pdf
Autor:
Vasileios Kourafalos, Eleonora Allocati, Luka Voncina, Brian Godman, Arianit Jakupi, Robert Plisko, Evelien Moorkens, Kateřina Kohoutová, Nataša Grubiša, Gisbert Selke, Anita Viksna, Arnold G. Vulto, Jurij Fürst, Jaana E. Martikainen, Leona Popelková, Ileana Mardare, Patricia Vella Bonanno, Vincent Suttorp, Dorthe Bartels, Sarah Mörtenhuber, Ott Laius, Iris Hoxha, Gustaf Befrits, Isabelle Huys, Dmitry Meshkov, Gnosia Achniotou, Rannveig Einarsdóttir, Øyvind Melien, Juraj Slabý, Ieva Greičiūtė-Kuprijanov, Simon Keuerleber, Einar Magnusson, Corinne Zara, Admir Malaj, Robert Puckett, Silvia Stockinger, Vanda Marković-Peković, Maria Dimitrova, Vera Vlahović Palčevski, Konstantin Tachkov, Tanja Novakovic, Roisin Adams, Roberta Joppi
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2021)
Frontiers in Pharmacology, 11:591134. Frontiers Media S.A.
Frontiers in Pharmacology
Volume 11
Frontiers in Pharmacology, 11:591134. Frontiers Media S.A.
Frontiers in Pharmacology
Volume 11
Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry.Objectives: The aim of thi
Autor:
Ruaraidh Hill, Christian Hierländer, Carolina Zampirolli Dias, Tomasz Bochenek, Ott Laius, Lars L. Gustafsson, Tracey-Lea Laba, Arianit Jakupi, Øyvind Melien, Wija Oortwijn, Luka Voncina, Durhane Wong-Rieger, Caridad Pontes, Jf Hans Piepenbrink, Magdalene Wladysiuk, Guenka Petrova, Patricia Vella Bonanno, Corinne Zara, Robert Sauermann, Steven Simoens, Olayinka O Ogunleye, Amanj Kurdi, Wouter Hamelinck, Wania Cristina Silva, Dzintars Gotham, Seung Jin Bae, Johanna C Meyer, Roberta Joppi, Janet Wale, Admir Malaj, John Yfantopoulos, Gisbert Selke, Angela Timoney, Brian Godman, Vincent de Valk, Andrew Hill, Merce Obach Cortadellas, D Tomek, Hye-Young Kwon, Irene Langner, Jurij Fürst, Iva Selke Krulichová, Antony P. Martin, Jolanta Gulbinovič, Iris Hoxha, Eleonora Allocati, Stuart McTaggart, Ieva Greiciute-Kuprijanov, Vanda Marković-Peković, Ileana Mardare
Publikováno v:
Expert review of pharmacoeconomics and outcomes research, Abingdon : Taylor and Francis Ltd., 2021, vol. 21, iss. 4, p. 527-540
Expert Review of Pharmacoeconomics and Outcomes Research, 21, 527-540
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
Expert Review of Pharmacoeconomics and Outcomes Research, 21, 4, pp. 527-540
Expert review of pharmacoeconomics & outcomes research
Expert Review of Pharmacoeconomics and Outcomes Research, 21, 527-540
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
Expert Review of Pharmacoeconomics and Outcomes Research, 21, 4, pp. 527-540
Expert review of pharmacoeconomics & outcomes research
Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dfe77330e4296c7333cde6b78e19b86
https://repository.vu.lt/VU:ELABAPDB88291411&prefLang=en_US
https://repository.vu.lt/VU:ELABAPDB88291411&prefLang=en_US
Autor:
Evelien, Moorkens, Brian, Godman, Isabelle, Huys, Iris, Hoxha, Admir, Malaj, Simon, Keuerleber, Silvia, Stockinger, Sarah, Mörtenhuber, Maria, Dimitrova, Konstantin, Tachkov, Luka, Vončina, Vera Vlahović, Palčevski, Gnosia, Achniotou, Juraj, Slabý, Leona, Popelková, Kateřina, Kohoutová, Dorthe, Bartels, Ott, Laius, Jaana E, Martikainen, Gisbert W, Selke, Vasileios, Kourafalos, Einar, Magnússon, Rannveig, Einarsdóttir, Roisín, Adams, Roberta, Joppi, Eleonora, Allocati, Arianit, Jakupi, Anita, Viksna, Ieva, Greičiūtė-Kuprijanov, Patricia, Vella Bonanno, Vincent, Suttorp, Øyvind, Melien, Robert, Plisko, Ileana, Mardare, Dmitry, Meshkov, Tanja, Novakovic, Jurij, Fürst, Corinne, Zara, Vanda, Marković-Peković, Nataša, Grubiša, Gustaf, Befrits, Robert, Puckett, Arnold G, Vulto
Publikováno v:
Frontiers in Pharmacology
Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry. Objectives: The aim of th
Autor:
Stuart McTaggart, Irene Langer, Ieva Greiciute-Kuprijanov, Patricia Vella Bonanno, Anne Marthe Ringerud, Angela Timoney, Jurij Fürst, John Yfantopoulos, Arianit Jakupi, Tatjana Ponorac, Robert Sauermann, Vanda Marković-Peković, Dzintars Gotham, D Tomek, Admir Malaj, Corinne Zara, Christian Hierländer, Peter Skiold, Vincent de Valk, Guenka Petrova, Antony P. Martin, JF (Hans) Piepenbrink, Jolanta Gulbinovič, Janet Wale, Iris Hoxha, Wouter Hamelinck, Maria Juhasz-Haverinen, Nataša Grubiša, Steven Simoens, Catherine Sermet, Ott Laius, Gisbert Selke, Robert Plisko, Celia C. Rothe, Tomasz Bochenek, Andrew F. Hill, Tanja Novakovic, Zornitza Mitkova, Ileana Mardare, Alan Haycox, Roberta Joppi, Carolin Hagen, Magdalene Wladysiuk, Amanj Kurdi, Elita Poplavska, Brian Godman, Merce Obach Cortadellas, Mark Parker
Publikováno v:
Generics and Biosimilars Initiative Journal
Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability. The enhanced use of low cost generics could help. Aims: Consequently, there is a need to compreh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0009ea13d1e0e5433c3f43ffb8a0034b
https://ruj.uj.edu.pl/xmlui/handle/item/257394
https://ruj.uj.edu.pl/xmlui/handle/item/257394
Publikováno v:
The Journal of Infection in Developing Countries. 9:094-098
Introduction: Health institutions in Albania have recently reported an increase in antibiotic misuse and microbial resistance. Until now, there have been no comprehensive studies that analyzed the overall use of antibiotics in Albania. The aim of thi